A Pharmaceopidemiological Study in Patients Who Use Symbicort SMART

AstraZeneca

Status: Completed

Conditions: Bronchial Asthma

Study type: Observational

Funder types: Industry

Identifiers

NCT00503061

GPRD

D5890C00017

Details and patient eligibility

About

To investigate how common it is that patients using Symibort SMART take high average daily doses that are not considered appropriate by their physician (overuse) or are hospitalised due to their asthma at least partly due to underuse.

Enrollment: 1,000 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Asthma diagnosis, patient registered with the prescribing physician for at least one year before the qualifying prescription of Symbicort, prescription of Symbicort SMART after UK launch of the concept

Exclusion criteria

• None